Clear Cell Borderline Ovarian Tumor: Clinical Characteristics, Prognosis, and Management

Background Clear cell borderline ovarian tumor (CCBOT) is one of the rarest subtypes of borderline ovarian malignancies. The aim of this study was to determine the prognosis of a series of CCBOT. Patients and Methods A retrospective review of patients with CCBOT treated or referred to our institutions. A centralized histological review by a reference pathologist and data on the clinical characteristics, management, and outcomes of patients were required for inclusion.

Nineteen patients were identified. Median age was 62 (range 36–83) years. Four patients underwent a conservative surgery and 14 a bilateral salpingo-oophorectomy +/– hysterectomy (unknown in 1 case). One patient had bilateral tumor, and all cases were stage-I disease. All CCBOTs showed an adenofibromatous pattern. Stromal microinvasion was observed in seven cases and intraepithelial carcinoma in two cases. Endometriosis was histologically associated in one case. The median follow-up was 76 (range 6–231) months. No recurrence occurred. Two patients died of intercurrent disease.

Peritoneal staging procedures should always be associated, but restaging surgery could be omitted if there was no suspicious lesion in the peritoneum during initial surgery, since all patients reported had stage-I disease. Fertility-sparing surgery appears to be a safe alternative in young patients. Synchronous endometrial disorders with atypia are infrequent. Prognosis is generally excellent, and long-term risk of recurrence is low. The two recurrences described in literature occurred in stage-IC diseases, highlighting the importance of avoiding perioperative rupture. Similar content being viewed by others

Kurman RJ, Carcangiu ML, Simon Herrington C, Young RH. WHO Classification of Tumours of Female Reproductive Organs. Vol 4th. 5th ed.; 2020. Uzan C, Dufeu-Lefebvre M, Fauvet R, et al. Management and prognosis of clear cell borderline ovarian tumor. Int J Gynecol Cancer. 2012;22(6):993–9. https://doi.org/10.1097/IGC.0b013e3182534acf. Bell DA, Scully RE. Benign and borderline clear cell adenofibromas of the ovary. Cancer. 1985;56(12):2922–31. https://doi.org/10.1002/1097-0142(19851215)56:12%3c2922::aid-cncr2820561233%3e3.0.co;2-l. Cakir E, Aydin E, Durmus NI, Samdanci E, Sahin N, Nurkabul Z. Primary ovarian clear cell adenofibroma of borderline malignancy. Oman Med J. 2012. https://doi.org/10.5001/omj.2012.20. Hada T, Miyamoto M, Ishibashi H, et al. Clear cell borderline tumor without fibromatous component: pathological and literature review and report of two cases. Mol Clin Oncol. 2021;14(4):75. https://doi.org/10.3892/mco.2021.2237. Ji H, Yliskoski M, Anttila M, Syrjänen K, Saarikoski S. Management of stage-I borderline ovarian tumors. Int J Gynaecol Obstet. 1996;54(1):37–44. https://doi.org/10.1016/0020-7292(96)02674-4. Kaern J, Tropé CG, Abeler VM. A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities. Cancer. 1993;71(5):1810-1820. https://doi.org/10.1002/1097-0142(19930301)71:53.0.co;2-v Kao GF, Norris HJ. Unusual cystadenofibromas: endometrioid, mucinous, and clear cell types. Obstet Gynecol. 1979;54(6):729–36. Kato N, Sasou S, Motoyama T. Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol. 2006;19(1):83–9. https://doi.org/10.1038/modpathol.3800492. Katsube Y, Fujiwara H, Tanioka Y, Imajo M, Fujiwara A. Ovarian clear cell adenofibroma of borderline malignancy. A case report. Hiroshima J Med Sci. 1989;38(2):87–90. Kleebkaow P, Aue-aungkul A, Temtanakitpaisan A, Kietpeerakool C. Borderline clear cell adenofibroma of the ovary. Case Rep Pathol. 2017; doi: https://doi.org/10.1155/2017/3860107 Liu J-L, Chu P-Y, Yeh K-T, Huang R-H. Borderline clear cell adenofibroma with extensive hemorrhagic necrosis. Hematol Oncol Stem Cell Ther. 2010;3(3):158–60. https://doi.org/10.1016/S1658-3876(10)50026-8. Momotani K, Tanaka T, Iwai E, Kanda T, Munakata S, Ohmichi M. Ovarian clear cell adenofibromatous tumor of borderline malignancy associated with high levels of carbohydrate antigen 19–9. J Obstet Gynaecol Res. 2011;37(5):472–7. https://doi.org/10.1111/j.1447-0756.2010.01373.x. Roth LM, Langley FA, Fox H, Wheeler JE, Czernobilsky B. Ovarian clear cell adenofibromatous tumors. Benign, of low malignant potential, and associated with invasive clear cell carcinoma. Cancer. 1984;53(5):1156-1163. https://doi.org/10.1002/1097-0142(19840301)53:53.0.CO;2-2 Suzuki A, Shiozawa T, Mori A, Kimura K, Konishi I. Cystic clear cell tumor of borderline malignancy of the ovary lacking fibromatous components: report of two cases and a possible new histological subtype. Gynecol Oncol. 2006;101(3):540–4. https://doi.org/10.1016/j.ygyno.2005.12.039. Vasenwala SM, Ansari HA, Haider N, Rehman S, Khan T. Atypical proliferating clear cell adenofibroma of the ovary: a case report. Middle East J Cancer. 2013;4(2):87–90. Vasilakaki T, Skafida E, Arkoumani E, Grammatoglou X, Firfiris N, Manoloudaki K. Borderline clear cell adenofibroma of the ovary associated with ovarian endometriosis: a case report. Eur J Gynaecol Oncol. 2012;33(2):230–2. Vo TM, Duong KA, Tran LTH, Bui TC. Recurrence rate and associated factors of borderline ovarian tumors in the south of Vietnam. J Obstet Gynaecol Res. 2019;45(10): 2055-2061. https://doi.org/10.1111/jog.14072 Wong HF, Low JJH, Chua Y, Busmanis I, Tay EH, Ho TH. Ovarian tumors of borderline malignancy: a review of 247 patients from 1991 to 2004. Int J Gynecol Cancer. 2007;17(2):342–9. https://doi.org/10.1111/j.1525-1438.2007.00864.x. Zhao C, Wu LS-F, Barner R. Pathogenesis of ovarian clear cell adenofibroma, atypical proliferative (borderline) tumor, and carcinoma: clinicopathologic features of tumors with endometriosis or adenofibromatous components support two related pathways of tumor development. J Cancer. 2011;2:94-106. https://doi.org/10.7150/jca.2.94 Matsuo K, Machida H, Yamagami W, et al. Intraoperative capsule rupture, postoperative chemotherapy, and survival of women with stage I epithelial ovarian cancer. Obstet Gynecol. 2019;134(5):1017–26. https://doi.org/10.1097/AOG.0000000000003507. Ricotta G, Maulard A, Genestie C, et al. Brenner borderline ovarian tumor: a case series and literature review. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-021-09879-y. Author information Authors and Affiliations Contributions P.M. and S.G. conceived the study; S.G., P.M., and A.M. undertook surgical management; G.R. performed data acquisition; G.R. and P.M. performed analyses; G.R. and P.M. wrote the manuscript. All authors reviewed the manuscript, approved the final version, and are accountable for all aspects of the work. Corresponding author Ethics declarations Disclosure The authors declare that they have no conflicts of interest. Additional information Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Rights and permissions About this article Cite this article Ricotta, G., Maulard, A., Candiani, M. et al. Clear Cell Borderline Ovarian Tumor: Clinical Characteristics, Prognosis, and Management. Ann Surg Oncol 29, 1165–1170 (2022). https://doi.org/10.1245/s10434-021-10776-7 Received: Accepted: Published: Version of record: Issue date: DOI: https://doi.org/10.1245/s10434-021-10776-7